Why Are Valeant Pharmaceuticals Intl Inc. Shares in Absolute Free Fall?

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) may be misleading investors. The consequences could be disastrous.

| More on:
The Motley Fool

The U.S.-listed shares of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) plunged by roughly 35% on Wednesday (as of this writing), as a new report by Citron Research called the company’s business practices into question.

This could not come at a worse time for Valeant, which is facing increased scrutiny for its drug-pricing strategy. But this time the allegations have nothing to do with raising drug prices.

Some murky dealings

At the beginning of October, practically no one had heard of Philidor Rx Services. But Philidor is at the epicentre of Valeant’s latest controversy.

The story began when Valeant sent R&O Pharmacy—a small outfit just outside of Los Angeles—a letter demanding US$69.8 million for “invoiced amounts.” This was a strange request for R&O’s owners, since the pharmacy didn’t do any business with Valeant. So R&O filed suit against Valeant on October 6, claiming it didn’t owe the drug giant any money.

This is where Philidor comes in. The company describes itself as a “pharmacy administrator” with Valeant as its only client. Philador’s ownership structure is murky, but we found out on Monday that Valeant owns an option to acquire the company. We also found out Philador’s financial statements are consolidated into Valeant’s.

That provides an explanation for why R&O may owe Valeant money. In reality the pharmacy owes Philador money, and this debt is consolidated into Valeant’s financials. But this does not explain why Valeant has been so secretive.

Then on Wednesday Citron claimed that Philador owns R&O Pharmacy! It pointed to some very interesting facts to back up this statement. For example, Philador and R&O have the same patient privacy disclosure (they are even formatted in the same way), and have the same toll-free contact number.

What does all of this mean?

The web of ownership may be confusing by now, but if true, such a structure could allow Valeant to record false sales, thus inflating revenue. The trick would also allow Valeant to boost its stock price, which makes it easier for the company to make acquisitions. It’s a very tempting trick to use, but it can eventually lead to disastrous results.

Worst of all, it looks like Valeant has created several other companies that look a lot like Philador. So, this is certainly not a one-off issue.

At this point, nothing is proven. But Citron’s findings raise some very strong suspicions against Valeant, which is what the share price is reacting to. There will surely be more updates to come.

Could this be an opportunity to buy the stock?

After surging for years, Valeant’s stock has now reached a 52-week low, and the stock must look very cheap to a lot of people.

But Valeant has always been a risky bet to make, essentially because it there’s little visibility on the company’s true profitability. Now that these revelations have come about, the bet all of a sudden becomes reckless. You shouldn’t touch the shares with a 50-foot pole.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Benjamin Sinclair has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

Two seniors float in a pool.
Dividend Stocks

TFSA: How to Earn $1,890 in Annual Tax-Free Income

Plunk these investments into your TFSA to earn passive income and avoid the taxman.

Read more »

grow dividends
Investing

Here’s My Top 3 TSX Stocks to Buy Right Now

Even though the TSX has been rising, there are still some good bargains out there. Here are three top compounding…

Read more »

Target. Stand out from the crowd
Investing

Prediction: This Canadian Growth Stock Could Double by 2030

Alimentation Couche-Tard (TSX:ATD) is a top growth stock that could do well over the next six or so years.

Read more »

Businessman holding AI cloud
Tech Stocks

Could Investing $20,000 in Nvidia Make You a Millionaire?

Nvidia stock has made investors millionaires in the last 10 years. Is it too late to invest to become a…

Read more »

Engineers walk through a facility.
Dividend Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

AtkinsRéalis (TSX:ATRL) is one TSX stock I'd never invest in.

Read more »

money cash dividends
Stocks for Beginners

Have $500? 3 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now

If you're looking for cheap stocks, these three have a huge future ahead of them, all while costing far less…

Read more »

edit Woman in skates works on laptop
Dividend Stocks

3 No-Brainer Stocks to Buy Under $30

These three stocks all offer a huge deal for investors looking for dividends, as well as growth that will last.

Read more »

Business man on stock market financial trade indicator background.
Tech Stocks

1 Growth Stock Down 50 Percent to Buy Right Now

There are plenty of growth stocks in the market worth considering, but Shopify (TSX:SHOP) looks like one of the best…

Read more »